Company Description
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform.
The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer.
The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor.
Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
| Country | United States |
| Founded | 2018 |
| IPO Date | Nov 15, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Dr. Peter Blume-Jensen M.D., Ph.D. |
Contact Details
Address: 480 Arsenal Way, Suite 100 Watertown, Massachusetts 02472 United States | |
| Phone | 617-207-8979 |
| Website | acrivon.com |
Stock Details
| Ticker Symbol | ACRV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.50 |
| CIK Code | 0001781174 |
| CUSIP Number | 004890109 |
| ISIN Number | US0048901096 |
| Employer ID | 82-5125532 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter Blume-Jensen M.D., Ph.D. | Co-Founder, Chairman of the Board, Chief Executive Officer, President and Acting Chief Scientific Officer |
| Kristina Masson M.B.A., Ph.D. | Co-Founder, Executive Vice President of Business Operations, Site Head, Treasurer, Secretary and Director |
| Rasmus Holm-Jorgensen | Chief Financial Officer |
| Dr. Eric J. Devroe Ph.D. | Chief Operating Officer |
| Katharine Peterson CPA | Vice President of Finance and Accounting |
| Dr. Adam D. Levy M.B.A., Ph.D. | Senior Vice President and Head of Investor Relations and Corporate Affairs |
| Bruce Close | Vice President of Quality and Compliance |
| Mary-Alice Miller J.D. | Chief Legal Officer |
| Parvin Miah | Vice President and Head of Human Resources |
| Dr. Erick Gamelin M.D., Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| Apr 29, 2024 | EFFECT | Notice of Effectiveness |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 24, 2024 | 8-K | Current Report |
| Apr 17, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 15, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 11, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |